L-leucine, an essential amino acid which cannot be synthesized in mammals, has extensive applications in various fields. However, the large-scale production of L-leucine still faces various challenges in terms of strain and process optimization. In this study, E. coli A211 was used as the initial strain, and a double enhancement strategy of CRISPR-associated transposase genome integration and a plasmid was employed to enhance the L-leucine metabolic pathway. We constructed four engineered strains—E. coli A101, E. coli B201, E. coli CD301, and E. coli bcd401. The transcriptional levels of key genes (leuA, leuCD, leuB, and bcd) in L-leucine biosynthesis were significantly upregulated to boost L-leucine production. Fermentation screening revealed that E. coli CD301 exhibited the highest L-leucine titer (0.57 ± 0.01 g/L), presenting a 97% increase compared with the parental strain. The fermentation process of E. coli CD301 was further optimized using single-factor optimization followed by response surface methodology of variables such as temperature, C/N ratio, and inoculum size, leading to an enhanced L-leucine titer of 0.89 ± 0.03 g/L, a 56.1% improvement over the pre-optimization level. This study demonstrated the effectiveness of CRISPR-associated transposase genome integration and plasmid double enhancement strategy, providing new insights into metabolic engineering approaches for improving L-leucine production via fermentation with E. coli.